Background Information

Claudin-18 (CLDN18) is a member of a large family of four-span transmembrane proteins called Claudins. These proteins are the essential components of the mammalian tight junctions (TJs) in epithelial cells. Claudin18 has two splice variants, 18.1 and 18.2. While CLDN18.1 is specifically expressed in the lung tissue, CLDN18.2 expression in normal tissue is more restricted and is only detected in small patches of stomach mucosal. CLDN18.2 expression is elevated in many types of epithelial cancers including stomach, esophagus, pancreatic and ovarian cancers. The expression of CLDN18.2 is not only detected in primary tumors, but also in the metastatic sites. Therefore, CLDN18.2 is an ideal target for monoclonal antibody-based cancer therapies.

Product Specifications

Representative Data

Detection of human CLDN18.2 expression on human CLDN18.2/MIA PaCa-2 stable cells using a monoclonal antibody specific for human CLDN18.2 at three different concentrations (2.5, 0.25 and 0.025 ug/ml).

References

---

Deer EL. et al. (2010) “Phenotype and genotype of pancreatic cancer cell lines”. Pancreas, 39(4):425.

Tureci O. et al. (2011) “Claudin-18 Gene Structure, Regulation, and Expression is Evolutionary Conserved in Mammals”. Gene, 481(2):83.

Sahin, U. et al. (2008) “Claudin-18 Splice Variant 2 is a Pan-Cancer Target Suitable for Therapeutic Antibody Development”. Clin. Cancer Res. 14(23):7624.

Niimi, T. et al. (2001) “Claudin-18, A Novel Downstream Target Gene for the T/ENB/NKX2.1 Homerodomain Transcription Factor, Encodes Lung- and Stomach-Specific Isoforms Through Alternative Splicing”. Mol. Cell. Biol. 21(21):7380.